Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?
Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.
The iShares U.S. Pharmaceuticals ETF (IHE) and the Invesco Pharmaceuticals ETF (PJP) are two investment funds that target the pharmaceutical manufacturing sector in the United States. While both funds provide exposure to the same industry, they differ in their strategies and risk profiles.
The iShares U.S. Pharmaceuticals ETF employs a broad market-cap-weighted strategy, making it a more cost-effective and diversified option for investors. On the other hand, Invesco Pharmaceuticals ETF utilizes a dynamic selection methodology, focusing on value and growth characteristics among 30 stocks. This results in a distinct risk profile for investors.
Beta, a measure of price volatility relative to the S&P 500, is calculated based on monthly returns over the available fund history (up to five years). Comparing the betas of IHE and PJP will provide insight into their relative volatility.
The 1-year return represents the total return over the trailing 12 months, allowing investors to gauge the recent performance of each fund. Additionally, the dividend yield is the trailing-12-month distribution yield, which investors should consider when comparing income-generating potential.
In summary, IHE offers a lower-cost and more diversified entry into the drug manufacturing sector, while PJP provides a more concentrated selection of value and growth stocks within the same industry. Investors should consider these factors, along with beta and 1-year return, to determine which ETF might be the better buy for their specific investment goals.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
